<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Gene test interpretation: &lt;i&gt;APOL1&lt;/i&gt; (chronic kidney disease gene)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Gene test interpretation:
       <i>
        APOL1
       </i>
       (chronic kidney disease gene)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Gene test interpretation:
        <i>
         APOL1
        </i>
        (chronic kidney disease gene)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anthony Bleyer, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anne Slavotinek, MBBS, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Albert Q Lam, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 28, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H4252834735">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         This monograph discusses implications of genetic testing for the
         <em>
          APOL1
         </em>
         gene, which encodes apolipoprotein L-1 (ApoL1), a part of the ApoA1 lipoprotein component of high-density lipoprotein (HDL) [
         <a href="#rid1">
          1
         </a>
         ]. Apol1 contains a membrane pore-forming domain that can create an anion channel.
        </p>
        <p>
         <em>
          APOL1
         </em>
         variants developed under evolutionary pressure to help defend against parasites such as trypanosomes in sub-Saharan Africa (similar to protection against malaria by sickle cell trait) [
         <a href="#rid2">
          2
         </a>
         ]. Heterozygous individuals are protected, but individuals with biallelic risk alleles have an increased risk for hypertension and chronic kidney disease (CKD) [
         <a href="#rid2">
          2,3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3863913626">
         <span class="h2">
          <i>
           APOL1
          </i>
          variants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two specific
         <em>
          APOL1
         </em>
         risk alleles (haplotypes) are associated with increased kidney disease risk [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          G1
         </strong>
         – G1 contains two single nucleotide variants (rs73885319 and rs60910145) that each result in an amino acid substitution. The Ser342Gly variant (rs73885319) substitutes glycine for the typical serine at amino acid 342, and the Ile384Met variant (rs60910145) substitutes methionine for the typical isoleucine at amino acid 384. These variants are located very close to each other and are in linkage disequilibrium, meaning they are inherited together in the same haplotype. Approximately 21 percent of Black individuals carry this haplotype.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          G2
         </strong>
         – G2 contains the rs71785313 variant, a six base pair deletion that eliminates two amino acids, asparagine at amino acid 388 and tyrosine at 389 (designated delAsn388 and delTyr389). Approximately 13 percent of Black individuals carry this haplotype.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          G0
         </strong>
         – G0 refers to a low-risk haplotype that does not contribute to CKD risk.
        </p>
        <p>
        </p>
        <p>
         Each individual has two
         <em>
          APOL1
         </em>
         alleles: one inherited on the paternal chromosome and one on the maternal chromosome. For each allele, the patient may inherit the G0, G1, or G2 haplotype; G1 and G2 will not be present on the same allele [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Biallelic risk haplotypes (G1 and G1, G1 and G2, or G2 and G2) markedly increase the risk of CKD and end-stage kidney disease (ESKD); this is referred to as a high-risk genotype [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="local">
          'CKD risk'
         </a>
         below.)
        </p>
        <p>
         The G1 or G2 haplotype on one allele and G0 on the other allele is a heterozygous carrier state; increased risk of ESKD has not been identified. Evolutionary pressure for heterozygosity is noted above. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3998975979">
         <span class="h2">
          CKD risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         Black individuals constitute 13 to 14 percent of the United States population and 30 percent of the ESKD population. Approximately 13 percent of Black individuals (&gt;5 million people) have a high-risk
         <em>
          APOL1
         </em>
         genotype, with biallelic G1 and/or G2 haplotypes. High-risk
         <em>
          APOL1
         </em>
         genotype accounts for approximately 70 percent of the excess ESKD risk [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Individuals with a high-risk
         <em>
          APOL1
         </em>
         genotype have a 15 to 30 percent chance of developing ESKD over their lifetime [
         <a href="#rid2">
          2
         </a>
         ]. In a case control study of 1825 African Americans, 6.7 percent with a high-risk genotype had an estimated glomerular filtration rate (eGFR) &lt;60 ml/min/1.73m
         <sup>
          2
         </sup>
         , versus 1.7 percent of Black individuals without the high-risk genotype [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         However, two-thirds of individuals with a high-risk genotype will not develop ESKD. Additional acquired and/or genetic contributions may occur.
        </p>
        <p>
         A high-risk genotype confers increased risk for certain forms of CKD, often before age 50 years [
         <a href="#rid2">
          2,4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HIV nephropathy
         </strong>
         – 29- to 89-fold increased risk compared with HIV-positive controls [
         <a href="#rid7">
          7,8
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypertension and hypertension-associated CKD or ESKD
         </strong>
         – Sevenfold increased risk [
         <a href="#rid4">
          4
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Focal segmental glomerulosclerosis (FSGS)
         </strong>
         – 17-fold increased risk [
         <a href="#rid7">
          7
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Microalbuminuria
         </strong>
         – Two- to threefold increased risk [
         <a href="#rid6">
          6
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         High-risk genotypes were documented in approximately 79 percent of Black individuals with HIV nephropathy, 50 percent of Black individuals with hypertensive CKD, 75 percent of Black individuals with FSGS, and 17 percent with microalbuminuria [
         <a href="#rid2">
          2,4,6,8
         </a>
         ]. In kidney transplant recipients,
         <em>
          APOL1
         </em>
         genotype did not affect graft survival in one study and appeared to be associated with decreased allograft survival in another [
         <a href="#rid9">
          9-11
         </a>
         ].
        </p>
        <p>
         Inflammation may be a triggering factor for
         <em>
          APOL1
         </em>
         nephropathy in individuals with the high-risk genotype. Collapsing FSGS has been described in an infant with STING syndrome (stimulator of interferon genes-associated vasculopathy) and in adults following parvovirus or COVID-19, or rarely after COVID-19 vaccination (two cases) [
         <a href="#rid12">
          12-16
         </a>
         ]. The risk from COVID-19 greatly outweighs the risk of a vaccine complication. (See
         <a class="local">
          'Prevention and management interventions'
         </a>
         below.)
        </p>
        <p>
         In a study of 138 children and young adults with FSGS, a high-risk
         <em>
          APOL1
         </em>
         genotype was associated with a greater risk of progression to ESKD but did not affect response to
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         or
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         [
         <a href="#rid17">
          17
         </a>
         ]. In another study, individuals with a high-risk
         <em>
          APOL1
         </em>
         genotype had worse outcomes that were not improved with aggressive blood pressure control [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3932299922">
         <span class="h1">
          COUNSELING AND DISCLOSURE OF RESULTS
         </span>
        </p>
        <p class="headingAnchor" id="H456684943">
         <span class="h2">
          Pre-test considerations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Testing may be done for several reasons:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation of kidney disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Potential kidney donor
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation for an unrelated condition
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Testing after a finding in a relative
        </p>
        <p>
        </p>
        <p>
         Clinicians should not order a genetic test if they are not comfortable and proficient at discussing results or if they lack a predetermined plan for delivering results.
        </p>
        <p>
         Prior to testing, clinicians should discuss risks, benefits, and alternatives to testing, and the option not to receive the results. Kidney donors may not want to know they have a high-risk genotype. (See
         <a class="local">
          'Kidney donation'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/96539.html" rel="external">
          "Secondary findings from genetic testing", section on 'Informed consent'
         </a>
         .)
        </p>
        <p>
         Some companies that perform genetic testing provide genetic counseling that can be very helpful.
        </p>
        <p class="headingAnchor" id="H1190109765">
         <span class="h2">
          Reviewing genetic test results
         </span>
         <span class="headingEndMark">
          —
         </span>
         Verify the result applies to the tested individual and testing was performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified or other nationally certified laboratory  (
         <a class="graphic graphic_table graphicRef122437" href="/z/d/graphic/122437.html" rel="external">
          table 1
         </a>
         ). Determine if a risk variant (G1 and/or G2) is present on one or both
         <em>
          APOL1
         </em>
         alleles. (See
         <a class="local">
          'APOL1 variants'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1009722746">
         <span class="h2">
          Information for the tested individual
         </span>
         <span class="headingEndMark">
          —
         </span>
         While disclosure of actionable genetic test results is well-accepted, uncertainty is greater for disclosure of results such as
         <em>
          APOL1
         </em>
         genotype, since kidney disease may not develop and management interventions are limited. Learning the results of
         <em>
          APOL1
         </em>
         genotype may improve outcomes; in a randomized trial involving &gt;2000 participants with hypertension, those assigned to disclosure had greater improvements in blood pressure control and biomarkers of chronic kidney disease (CKD) [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         If a patient undergoes genetic testing for
         <em>
          APOL1
         </em>
         or is referred specifically for explanation of genetic results, the provider should ascertain that pre-test counseling was performed and provide counseling if not done previously (see
         <a class="local">
          'Pre-test considerations'
         </a>
         above). Even after testing, the patient can decline to receive the results, though in some cases the result may be entered into the medical record and inadvertently disclosed in the future.
        </p>
        <p>
         For individuals who wish to receive the results, a clear and supportive discussion of the findings, implications, and potential management strategies is essential. The algorithm  (
         <a class="graphic graphic_algorithm graphicRef138833" href="/z/d/graphic/138833.html" rel="external">
          algorithm 1
         </a>
         ) and table  (
         <a class="graphic graphic_table graphicRef138729" href="/z/d/graphic/138729.html" rel="external">
          table 2
         </a>
         ) summarize important considerations and information to provide, which include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Delivery of the information by a health professional who has a relationship with the patient and is knowledgeable about the testing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Communication of results realistically, with empathy, hopefulness, and an understanding of the patient's basic genetic knowledge.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The discussion must consider the historical mistreatment of Black individuals in research, clinical care, and genetic testing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The term "mutation" is discouraged; "genetic variant" or "risk variant" is more appropriate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients should be aware of legal protections against health care discrimination, as well as areas in which they are not protected. (See
         <a class="local">
          'Life insurance coverage (in the United States)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H435024621">
         <span class="h2">
          Psychological effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients may develop anxiety after learning they have a high-risk
         <em>
          APOL1
         </em>
         genotype. This usually dissipates over several months.
        </p>
        <p>
         In a study of 76 African American community members, stakeholders strongly supported returning results, but risks include misunderstanding, psychological burdens, and stigma [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3646760190">
         <span class="h2">
          Life insurance coverage (in the United States)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with known kidney disease may be denied life insurance coverage or have higher costs. Additional information about a high-risk
         <em>
          APOL1
         </em>
         genotype is unlikely to further increase these costs.
        </p>
        <p>
         However, patients
         <strong>
          without
         </strong>
         known CKD who undergo genetic testing are at risk for adverse consequences when trying to obtain life insurance and long-term care insurance. This is especially concerning for potential kidney donors, who are trying to perform an altruistic act. Patients tested for unrelated conditions who are found to have
         <em>
          APOL1
         </em>
         risk alleles may also be at risk from learning this information.
        </p>
        <p>
         Protections against discrimination exist for health insurance and employment. (See
         <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">
          "Genetic testing", section on 'Genetic discrimination'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3607912429">
         <span class="h2">
          Kidney donation
         </span>
         <span class="headingEndMark">
          —
         </span>
         In kidney transplant, the risk of graft failure is increased when the donor kidney has a high-risk
         <em>
          APOL1
         </em>
         genotype, with an almost fourfold increased risk of progression to graft loss over time [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         Given the increased risk of graft failure and the increased risk of the donor developing end-stage kidney disease (ESKD), many centers are not allowing patients with the high-risk
         <em>
          APOL1
         </em>
         genotype to donate, especially if the donor is young.
        </p>
        <p>
         Kidney donors should have the option of not receiving
         <em>
          APOL1
         </em>
         genetic test results; however, many will be curious as to the reason they are turned down for donation. (See
         <a class="local">
          'Pre-test considerations'
         </a>
         above.)
        </p>
        <p>
         Positive results can result in uncertainty regarding the potential to develop CKD. Kidney transplant programs should have a protocol in place for delivering these results. (See
         <a class="local">
          'Information for the tested individual'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1240751598">
         <span class="h1">
          CLINICAL CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals with a high-risk
         <em>
          APOL1
         </em>
         genotype (homozygous or compound heterozygous for risk alleles) are at increased risk of CKD, although the majority will never develop CKD. (See
         <a class="local">
          'CKD risk'
         </a>
         above.)
        </p>
        <p>
         Individuals who are heterozygous for a risk allele are not considered at increased risk. (See
         <a class="local">
          'APOL1 variants'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2241974369">
         <span class="h2">
          Evaluation and monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with a high-risk
         <em>
          APOL1
         </em>
         genotype should receive reassurance and have their questions answered to alleviate anxiety. (See
         <a class="local">
          'Counseling and disclosure of results'
         </a>
         above and
         <a class="local">
          'Psychological effects'
         </a>
         above.)
        </p>
        <p>
         They should undergo the following testing  (
         <a class="graphic graphic_algorithm graphicRef138833" href="/z/d/graphic/138833.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Kidney function
         </strong>
         – Serum creatinine, urinalysis, and urinary albumin (or microalbumin) to creatinine ratio at least annually (more frequently as needed for patient reassurance). Urinary albumin or microalbumin alone without urinary creatinine is insufficient.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Blood pressure
         </strong>
         – All individuals should have blood pressure measured; the patient should buy a blood pressure cuff and check blood pressure at least monthly.
        </p>
        <p>
        </p>
        <p>
         It is also appropriate to evaluate for any chronic inflammatory conditions that might exacerbate CKD. (See
         <a class="local">
          'CKD risk'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3934069939">
         <span class="h2">
          Prevention and management interventions
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no consensus for the care of patients with a high-risk
         <em>
          APOL1
         </em>
         genotype. Many groups are evaluating potential treatments for
         <em>
          APOL1
         </em>
         nephropathy and trying to identify inciting causes; the investigational Apol1 channel blocker inaxaplin appears promising [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         Patients should be informed about ongoing research and potential new therapies  (
         <a class="graphic graphic_table graphicRef138729" href="/z/d/graphic/138729.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         General health guidelines should be followed:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoid smoking
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Regular exercise
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maintain a healthy body weight and body mass index
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treat other health conditions
        </p>
        <p>
        </p>
        <p>
         Hypertension should be treated with similar targets as in patients without a high-risk
         <em>
          APOL1
         </em>
         haplotype  (
         <a class="graphic graphic_algorithm graphicRef138833" href="/z/d/graphic/138833.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
         In one study, Black individuals with a high-risk genotype had a twofold increased risk of acute kidney injury (AKI) and death from COVID-19 [
         <a href="#rid16">
          16
         </a>
         ]. Vaccination to prevent COVID-19 should be offered to individuals with a high-risk genotype. (See
         <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">
          "COVID-19: Vaccines"
         </a>
         .)
        </p>
        <p>
         Patients considering kidney donation should receive counseling about
         <em>
          APOL1
         </em>
         testing and should consider being tested prior to donation with counseling on the risks and benefits of testing. (See
         <a class="local">
          'Counseling and disclosure of results'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1946336077">
         <span class="h1">
          FIRST-DEGREE RELATIVES
         </span>
         <span class="headingEndMark">
          —
         </span>
         First-degree relatives may consider
         <em>
          APOL1
         </em>
         testing. No specific treatments are available, but those with a risk allele may benefit from the measures discussed above. (See
         <a class="local">
          'Evaluation and monitoring'
         </a>
         above and
         <a class="local">
          'Prevention and management interventions'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1218240965">
         <span class="h1">
          RESOURCES
         </span>
        </p>
        <p class="headingAnchor" id="H1636068316">
         <span class="h2">
          Locating a specialist
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical geneticists
         </strong>
         – American College of Medical Genetics and Genomics (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=135174" target="_blank">
          ACMG
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic counselors
         </strong>
         – National Society of Genetic Counselors (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F%3Freload%3Dtimezone&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflzQ%2BZ4POBsSFXQiuwJDn5pefBPIAES8nVSzeVi4Tr3mXQ%3D%3D&amp;TOPIC_ID=135174" target="_blank">
          NSGC
         </a>
         ). Genetic testing laboratories may also provide virtual (online or telephone) access to a genetic counselor.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H399719605">
         <span class="h2">
          UpToDate topics
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          FSGS
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/117559.html" rel="external">
          "Focal segmental glomerulosclerosis: Genetic causes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/117558.html" rel="external">
          "Focal segmental glomerulosclerosis: Pathogenesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3049.html" rel="external">
          "Focal segmental glomerulosclerosis: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3100.html" rel="external">
          "Focal segmental glomerulosclerosis: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HIV-associated
         </strong>
         <strong>
          nephropathy
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/14026.html" rel="external">
          "HIV-associated nephropathy (HIVAN)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lupus nephritis
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/3056.html" rel="external">
          "Lupus nephritis: Diagnosis and classification"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3093.html" rel="external">
          "Lupus nephritis: Therapy of lupus membranous nephropathy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3059.html" rel="external">
          "Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sickle cell nephropathy
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7199.html" rel="external">
          "Sickle cell disease effects on the kidney"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Kidney transplant
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7315.html" rel="external">
          "Kidney transplantation in adults: Evaluation of the living kidney donor candidate"
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman DJ, Pollak MR. APOL1 Nephropathy: From Genetics to Clinical Applications. Clin J Am Soc Nephrol 2021; 16:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daneshpajouhnejad P, Kopp JB, Winkler CA, Rosenberg AZ. The evolving story of apolipoprotein L1 nephropathy: the end of the beginning. Nat Rev Nephrol 2022; 18:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reidy KJ, Hjorten R, Parekh RS. Genetic risk of APOL1 and kidney disease in children and young adults of African ancestry. Curr Opin Pediatr 2018; 30:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman DJ, Kozlitina J, Genovese G, et al. Population-based risk assessment of APOL1 on renal disease. J Am Soc Nephrol 2011; 22:2098.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kopp JB, Nelson GW, Sampath K, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 2011; 22:2129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasembeli AN, Duarte R, Ramsay M, et al. APOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South Africans. J Am Soc Nephrol 2015; 26:2882.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freedman BI, Moxey-Mims M. The APOL1 Long-Term Kidney Transplantation Outcomes Network-APOLLO. Clin J Am Soc Nephrol 2018; 13:940.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee BT, Kumar V, Williams TA, et al. The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival. Am J Transplant 2012; 12:1924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang Z, Sun Z, Fu J, et al. Recipient APOL1 risk alleles associate with death-censored renal allograft survival and rejection episodes. J Clin Invest 2021; 131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abid Q, Best Rocha A, Larsen CP, et al. APOL1-Associated Collapsing Focal Segmental Glomerulosclerosis in a Patient With Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset in Infancy (SAVI). Am J Kidney Dis 2020; 75:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Besse W, Mansour S, Jatwani K, et al. Collapsing glomerulopathy in a young woman with APOL1 risk alleles following acute parvovirus B19 infection: a case report investigation. BMC Nephrol 2016; 17:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roy S, Kunaparaju S, Koduri NM, et al. COVID-19 and APOL-1 High-Risk Genotype-Associated Collapsing Glomerulonephritis. Case Rep Nephrol 2021; 2021:3737751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caza TN, Cassol CA, Messias N, et al. Glomerular Disease in Temporal Association with SARS-CoV-2 Vaccination: A Series of 29 Cases. Kidney360 2021; 2:1770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hung AM, Shah SC, Bick AG, et al. APOL1 Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program. JAMA Intern Med 2022; 182:386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kopp JB, Winkler CA, Zhao X, et al. Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial. J Am Soc Nephrol 2015; 26:1443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parsa A, Kao WH, Xie D, et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 2013; 369:2183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nadkarni GN, Fei K, Ramos MA, et al. Effects of Testing and Disclosing Ancestry-Specific Genetic Risk for Kidney Failure on Patients and Health Care Professionals: A Randomized Clinical Trial. JAMA Netw Open 2022; 5:e221048.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           West KM, Cavanaugh KL, Blacksher E, et al. Stakeholder Perspectives on Returning Nonactionable Apolipoprotein L1 (APOL1) Genetic Results to African American Research Participants. J Empir Res Hum Res Ethics 2022; 17:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reeves-Daniel AM, DePalma JA, Bleyer AJ, et al. The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant 2011; 11:1025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Egbuna O, Zimmerman B, Manos G, et al. Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants. N Engl J Med 2023; 388:969.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 135174 Version 6.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32616495" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : APOL1 Nephropathy: From Genetics to Clinical Applications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35217848" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The evolving story of apolipoprotein L1 nephropathy: the end of the beginning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20647424" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Association of trypanolytic ApoL1 variants with kidney disease in African Americans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29406442" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Genetic risk of APOL1 and kidney disease in children and young adults of African ancestry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21997396" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Population-based risk assessment of APOL1 on renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21997394" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25788523" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : APOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South Africans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29703792" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The APOL1 Long-Term Kidney Transplantation Outcomes Network-APOLLO.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22487534" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34499625" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Recipient APOL1 risk alleles associate with death-censored renal allograft survival and rejection episodes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31601430" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : APOL1-Associated Collapsing Focal Segmental Glomerulosclerosis in a Patient With Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset in Infancy (SAVI).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27600725" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Collapsing glomerulopathy in a young woman with APOL1 risk alleles following acute parvovirus B19 infection: a case report investigation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34367703" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : COVID-19 and APOL-1 High-Risk Genotype-Associated Collapsing Glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35372991" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Glomerular Disease in Temporal Association with SARS-CoV-2 Vaccination: A Series of 29 Cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35089317" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : APOL1 Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25573908" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24206458" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : APOL1 risk variants, race, and progression of chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35244702" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Effects of Testing and Disclosing Ancestry-Specific Genetic Risk for Kidney Failure on Patients and Health Care Professionals: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34870514" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Stakeholder Perspectives on Returning Nonactionable Apolipoprotein L1 (APOL1) Genetic Results to African American Research Participants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21486385" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The APOL1 gene and allograft survival after kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36920755" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
